Fexofenadine Overcomes Osimertinib Resistance by Inhibiting c-Met in Non-Small Cell Lung Cancer

Abstract

Osimertinib is the only third-generation EGFR tyrosine kinase inhibitor clinically approved for first-line treatment of advanced NSCLC patients harboring EGFR mutations. However, drug resistance severely hinders its clinical efficacy. Acquired MET amplification is an important mechanism causing osimertinib resistance. This study is the first to identify fexofenadine, originally indicated for allergic rhinitis and chronic urticaria, as a putative Met-inhibitor by in silico chemical-protein interactome analysis of known Met inhibitors. Fexofenadine was verified to inhibit recombinant Met kinase in cell-free assay and phosphorylation of Met and other downstream signaling molecules in osimertinib-resistant NSCLC cell lines. KINOME profiling revealed a similar kinase inhibition profile between fexofenadine and a known Met-inhibiting drug cabozantinib using Spearman rank-order correlation analysis. Among the tested osimertinib-resistant NSCLC cell lines, fexofenadine was the most efficacious in potentiating osimertinib in NCI-H820 (having MET amplification and EGFR-T790M mutation). Transcriptome profiling in NCI-H820 revealed that the differentially expressed genes following fexofenadine treatment were enriched in epithelial-mesenchymal transition-related biological pathways. Importantly, fexofenadine was also shown to significantly potentiate the antitumor effect of osimertinib in a drug-refractory NSCLC patient-derived tumor xenograft model in NSG mice, without inducing notable adverse effects. These findings advocate the clinical evaluation of repurposing fexofenadine to overcome osimertinib resistance.

Keywords

DRAR-CPI / epithelial-mesenchymal transition / fexofenadine / Met / osimertinib

References

[1] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024): 12–49.

[2] R. Roskoski , “Small Molecule Inhibitors Targeting the EGFR/ErbB Family of Protein-Tyrosine Kinases in Human Cancers,” Pharmacological Research 139 (2019): 395–411.

[3] S. Halder, S. Basu, S. P. Lall, A. K. Ganti, S. K. Batra, and P. Seshacharyulu, “Targeting the EGFR Signaling Pathway in Cancer Therapy: What's New in 2023?,” Expert Opinion on Therapeutic Targets 27, no. 4–5 (2023): 305–324.

[4] E. Castellanos, E. Feld, and L. Horn, “Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer,” Journal of Thoracic Oncology 12, no. 4 (2017): 612–623.

[5] W. Q. Li and J. W. Cui, “Non-Small Cell Lung Cancer Patients With ex19del or exon 21 L858R Mutation: Distinct Mechanisms, Different Efficacies to Treatments,” Journal of Cancer Research and Clinical Oncology 146, no. 9 (2020): 2329–2338.

[6] J. Lee, Z. Piotrowska, R. Soo, B. C. Cho, and S. M. Lim, “Combatting Acquired Resistance to Osimertinib in EGFR-Mutant Lung Cancer,” Therapeutic Advances in Medical Oncology 14 (2022): 17588359221144099.

[7] H. Chhouri, D. Alexandre, and L. Grumolato, “Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer,” Cancers 15, no. 2 (2023): 504.

[8] S. Butterworth, D. A. E. Cross, M. R. V. Finlay, R. A. Ward, and M. J. Waring, “The Structure-Guided Discovery of Osimertinib: The First U.S. FDA Approved Mutant Selective Inhibitor of EGFR T790M,” MedChemComm 8, no. 5 (2017): 820–822.

[9] A. Murtuza, A. Bulbul, J. P. Shen, et al., “Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer,” Cancer Research 79, no. 4 (2019): 689–698.

[10] J. C. Soria and S. S. Ramalingam, “Osimertinib in EGFR Mutation-Positive Advanced NSCLC,” New England Journal of Medicine 378, no. 13 (2018): 1262–1263.

[11] Y. Cheng, Y. He, W. Li, et al., “Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, a Randomized Study,” Targeted Oncology 16, no. 2 (2021): 165–176.

[12] A. Leonetti, S. Sharma, R. Minari, P. Perego, E. Giovannetti, and M. Tiseo, “Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer,” British Journal of Cancer 121, no. 9 (2019): 725–737.

[13] H. Viray, A. J. Piper-Vallillo, P. Widick, et al., “A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated With First-Line Osimertinib: Expanding the FLAURA Trial Results Into Routine Clinical Practice,” Cancers 16, no. 6 (2024): 1079.

[14] K. Lee, D. Kim, S. Yoon, D. H. Lee, and S. W. Kim, “Exploring the Resistance Mechanisms of Second-Line Osimertinib and Their Prognostic Implications Using Next-Generation Sequencing in Patients With Non-Small-Cell Lung Cancer,” European Journal of Cancer 148 (2021): 202–210.

[15] G. R. Oxnard, Y. Hu, K. F. Mileham, et al., “Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib,” JAMA Oncology 4, no. 11 (2018): 1527–1534.

[16] S. Wang, Y. Song, and D. Liu, “EAI045: The Fourth-Generation EGFR Inhibitor Overcoming T790M and C797S Resistance,” Cancer Letters 385 (2017): 51–54.

[17] C. To, T. S. Beyett, J. Jang, et al., “An Allosteric Inhibitor Against the Therapy-Resistant Mutant Forms of EGFR in Non-Small Cell Lung Cancer,” Nature Cancer 3, no. 4 (2022): 402–417.

[18] Z. Zalaquett, M. Catherine Rita Hachem, Y. Kassis, et al., “Acquired Resistance Mechanisms to Osimertinib: The Constant Battle,” Cancer Treatment Reviews 116 (2023): 102557.

[19] A. Ferro, G. M. Marinato, C. Mulargiu, et al., “The Study of Primary and Acquired Resistance to First-Line Osimertinib to Improve the Outcome of EGFR-Mutated Advanced Non-Small Cell Lung Cancer Patients: The Challenge Is Open for New Therapeutic Strategies,” Critical Reviews in Oncology/Hematology 196 (2024): 104295.

[20] O. Miranda, M. Farooqui, and J. M. Siegfried, “Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer,” Cancers 10, no. 9 (2018): 280.

[21] A. Leonetti, M. Verzè, R. Minari, et al., “Resistance to Osimertinib in Advanced EGFR-Mutated NSCLC: A Prospective Study of Molecular Genotyping on Tissue and Liquid Biopsies,” British Journal of Cancer 130, no. 1 (2024): 135–142.

[22] N. Roper, R. El Meskini, T. Maity, et al., “Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-Resistant EGFR-Driven Lung Cancer,” Cancer Research Communications 4, no. 2 (2024): 337–348.

[23] P. Shi, Y. T. Oh, G. Zhang, et al., “Met Gene Amplification and Protein Hyperactivation Is a Mechanism of Resistance to Both First and Third Generation EGFR Inhibitors in Lung Cancer Treatment,” Cancer Letters 380, no. 2 (2016): 494–504.

[24] K. Wang, R. Du, S. Roy-Chowdhuri, et al., “Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC,” JTO Clinical and Research Reports 4, no. 8 (2023): 100533.

[25] L. Deng, L. A. Kiedrowski, E. Ravera, H. Cheng, and B. Halmos, “Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient With MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition,” Journal of Thoracic Oncology 13, no. 9 (2018): e169–e172.

[26] V. W. Zhu, A. B. Schrock, S. M. Ali, and S. I. Ou, “Differential Response to a Combination of Full-Dose Osimertinib and Crizotinib in a Patient With EGFR-Mutant Non-Small Cell Lung Cancer and Emergent MET Amplification,” Lung Cancer (Auckl) 10 (2019): 21–26.

[27] E. Bresso, A. Furlan, P. Noel, et al., “Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type,” Molecules 25, no. 4 (2020): 938.

[28] K. K. W. To and W. C. S. Cho, “Mesenchymal Epithelial Transition (MET): A Key Player in Chemotherapy Resistance and an Emerging Target for Potentiating Cancer Immunotherapy,” Current Cancer Drug Targets 22, no. 4 (2022): 269–285.

[29] F. Jin, Y. Lin, W. Yuan, et al., “Recent Advances in c-Met-Based Dual Inhibitors in the Treatment of Cancers,” European Journal of Medicinal Chemistry 272 (2024): 116477.

[30] H. Luo, J. Chen, L. Shi, et al., “DRAR-CPI: A Server for Identifying Drug Repositioning Potential and Adverse Drug Reactions via the Chemical-Protein Interactome,” Nucleic Acids Research 39, no. Web Server issue (2011): W492–W498.

[31] P. Iyer, J. Bolla, V. Kumar, M. S. Gill, and M. E. Sobhia, “In Silico Identification of Targets for a Novel Scaffold, 2-Thiazolylimino-5-Benzylidin-Thiazolidin-4-One,” Molecular Diversity 19, no. 4 (2015): 855–870.

[32] S. J. Chen, “A Potential Target of Tanshinone IIA for Acute Promyelocytic Leukemia Revealed by Inverse Docking and Drug Repurposing,” Asian Pacific Journal of Cancer Prevention 15, no. 10 (2014): 4301–4305.

[33] N. Coleman, A. Harbery, S. Heuss, I. Vivanco, and S. Popat, “Targeting Un-MET Needs in Advanced Non-Small Cell Lung Cancer,” Lung Cancer 164 (2022): 56–68.

[34] Y. B. Sang, G. Kim, S. Hwang, H. Kang, and H. J. Chon, “Dramatic Response to Cabozantinib in a Patient With Refractory Hepatocellular Carcinoma With c-MET Amplification,” Journal of Clinical and Translational Hepatology 11, no. 3 (2023): 747–750.

[35] F. Qian, S. Engst, K. Yamaguchi, et al., “Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases,” Cancer Research 69 (2009): 8009–8016.

[36] N. Munshi, S. Jeay, Y. Li, et al., “ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase With Antitumor Activity,” Molecular Cancer Therapeutics 9, no. 6 (2010): 1544–1553.

[37] L. Yang, J. Chen, and L. He, “Harvesting Candidate Genes Responsible for Serious Adverse Drug Reactions From a Chemical-Protein Interactome,” PLoS Computational Biology 5, no. 7 (2009): e1000441.

[38] T. Kubo, H. Yamamoto, W. W. Lockwood, et al., “MET Gene Amplification or EGFR Mutation Activate MET in Lung Cancers Untreated With EGFR Tyrosine Kinase Inhibitors,” International Journal of Cancer 124, no. 8 (2009): 1778–1784.

[39] Q. Qin, X. Li, X. Liang, et al., “Targeting the EMT Transcription Factor Snail Overcomes Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer,” Thoracic Cancer 12, no. 11 (2021): 1708–1715.

[40] I. Cañadas, F. Rojo, Á. Taus, et al., “Targeting Epithelial-to-Mesenchymal Transition With Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer,” Clinical Cancer Research 20, no. 4 (2014): 938–950.

[41] K. K.W. To and W. C. S. Cho, “Drug Repurposing for Cancer Therapy in the Era of Precision Medicine,” Current Molecular Pharmacology 15, no. 7 (2022): 895–903.

[42] R. M. Gomez, P. Moreno, E. Compalati, G. W. Canonica, and I. J. A. Zubeldia, “Update Meta-Analysis on the Efficacy and Safety Issues of Fexofenadine,” World Allergy Organization Journal 16, no. 7 (2023): 100795.

[43] I. Fritz, P. Wagner, and H. Olsson, “Improved Survival in Several Cancers With Use of H1-Antihistamines Desloratadine and Loratadine,” Translational Oncology 14, no. 4 (2021): 101029.

[44] H. Li, Y. Xiao, Q. Li, et al., “The Allergy Mediator Histamine Confers Resistance to Immunotherapy in Cancer Patients via Activation of the Macrophage Histamine Receptor H1,” Cancer Cell 40, no. 1 (2022): 36–52.e9.

[45] M. Sharma, A. O. Stucki, S. Verstraelen, et al., “Human Cell-Based In Vitro Systems to Assess Respiratory Toxicity: A Case Study Using Silanes,” Toxicological Sciences 195, no. 2 (2023): 213–230.

[46] G. Gomatou, N. Syrigos, and E. Kotteas, “Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options,” Cancers 15, no. 3 (2023): 841.

[47] E. Calvo, J. S. Lee, S. W. Kim, et al., “Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer,” Journal of Clinical Pharmacology 59, no. 8 (2019): 1099–1109.

[48] S. Van Hoppe, A. Jamalpoor, J. J. M. Rood, et al., “Brain Accumulation of Osimertinib and Its Active Metabolite AZ5104 Is Restricted by ABCB1 (P-Glycoprotein) and ABCG2 (Breast Cancer Resistance Protein),” Pharmacological Research 146 (2019): 104297.

[49] B. Wang, Y. Xiao, X. Yang, et al., “Protective Effect of Dihydromyricetin on LPS-Induced Acute Lung Injury,” Journal of Leukocyte Biology 103 (2018): 1241–1249.

[50] M. Shahid, A. Azfaralariff, D. Law, et al., “Comprehensive Computational Target Fishing Approach to Identify Xanthorrhizol Putative Targets,” Scientific Reports 11, no. 1 (2021): 1594.

[51] S. Chen, Y. Bi, and L. Zhang, “Systematic Analysis of the Potential Off-Target Activities of Osimertinib by Computational Target Fishing,” Anti-Cancer Drugs 33, no. 1 (2022): e434–e443.

[52] M. A. Fabian, W. H. Biggs III, D. K. Treiber, et al., “A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors,” Nature Biotechnology 23, no. 3 (2005): 329–336.

[53] W. Voigt, “Sulforhodamine B Assay and Chemosensitivity,” Methods in Molecular Medicine 110 (2005): 39–48.

[54] T. C. Chou, “Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies,” Pharmacological Reviews 58, no. 3 (2006): 621–681.

[55] R. Onozato, T. Kosaka, H. Kuwano, Y. Sekido, Y. Yatabe, and T. Mitsudomi, “Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers,” Journal of Thoracic Oncology 4, no. 1 (2009): 5–11.

[56] X. Zhao, B. A. Weir, T. LaFramboise, et al., “Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis,” Cancer Research 65, no. 13 (2005): 5561–5570.

[57] K. K. W. To, J. C. H. Chow, K. M. Cheung, and W. C. S. Cho, “Circumvention of Gefitinib Resistance by Repurposing Flunarizine via Histone Deacetylase Inhibition,” ACS Pharmacology & Translational Science 6, no. 10 (2023): 1531–1543.

[58] N. Floc'h, M. J. Martin, J. W. Riess, et al., “Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions,” Molecular Cancer Therapeutics 17, no. 5 (2018): 885–896.

[59] Z. N. Lei, Q. X. Teng, P. Gupta, et al., “Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model,” Frontiers in Cell and Developmental Biology 9 (2021): 640957.

[60] K. K. W. To, D. C. Poon, Y. Wei, F. Wang, G. Lin, and L. Fu, “Pelitinib (EKB-569) Targets the Up-Regulation of ABCB1 and ABCG2 Induced by Hyperthermia to Eradicate Lung Cancer,” British Journal of Pharmacology 172, no. 16 (2015): 4089–4106.

[61] X. Zheng, W. Wang, Y. Zhang, et al., “Development and Validation of a UPLC-MS/MS Method for Quantification of Osimertinib (AZD9291) and Its Metabolite AZ5104 in Human Plasma,” Biomedical Chromatography 32, no. 12 (2018): e4365.

[62] T. Chen, X. Chen, S. Zhang, et al., “The Genome Sequence Archive Family: Toward Explosive Data Growth and Diverse Data Types,” Genomics, Proteomics & Bioinformatics 19, no. 4 (2021): 578–583.

[63] CNCB-NGDC Members and Partners, “Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2024,” Nucleic Acids Research 52, no. D1 (2024): D18–D32.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).